- Home
- CWEN vs PRCT Comparison
CWEN vs PRCT Comparison
Compare CWEN & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- PRCT
- Stock Information
- Founded
- CWEN 2012
- PRCT 2009
- Country
- CWEN United States
- PRCT United States
- Employees
- CWEN N/A
- PRCT N/A
- Industry
- CWEN Electric Utilities: Central
- PRCT Medical Specialities
- Sector
- CWEN Utilities
- PRCT Health Care
- Exchange
- CWEN Nasdaq
- PRCT Nasdaq
- Market Cap
- CWEN 3.4B
- PRCT 3.2B
- IPO Year
- CWEN 2013
- PRCT 2021
- Fundamental
- Price
- CWEN $30.36
- PRCT $57.94
- Analyst Decision
- CWEN Strong Buy
- PRCT Strong Buy
- Analyst Count
- CWEN 4
- PRCT 7
- Target Price
- CWEN $35.75
- PRCT $90.00
- AVG Volume (30 Days)
- CWEN 863.2K
- PRCT 822.5K
- Earning Date
- CWEN 04-30-2025
- PRCT 04-24-2025
- Dividend Yield
- CWEN 5.64%
- PRCT N/A
- EPS Growth
- CWEN 20.79
- PRCT N/A
- EPS
- CWEN 0.79
- PRCT N/A
- Revenue
- CWEN $1,406,000,000.00
- PRCT $249,121,000.00
- Revenue This Year
- CWEN $7.88
- PRCT $47.40
- Revenue Next Year
- CWEN $10.82
- PRCT $31.81
- P/E Ratio
- CWEN $38.17
- PRCT N/A
- Revenue Growth
- CWEN 9.08
- PRCT 59.36
- 52 Week Low
- CWEN $24.02
- PRCT $47.04
- 52 Week High
- CWEN $31.09
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CWEN 55.75
- PRCT 53.99
- Support Level
- CWEN $30.13
- PRCT $54.72
- Resistance Level
- CWEN $31.02
- PRCT $59.19
- Average True Range (ATR)
- CWEN 0.69
- PRCT 2.62
- MACD
- CWEN 0.06
- PRCT 0.14
- Stochastic Oscillator
- CWEN 74.90
- PRCT 77.26
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.